de Lartigue Jane
Surrey, UK.
Drugs Today (Barc). 2011 Aug;47(8):583-90. doi: 10.1358/dot.2011.47.8.1635872.
Corifollitropin alfa (Elonva®) is the first hybrid follicle-stimulating hormone (FSH) molecule with demonstrated sustained follicle-stimulating activity. The β subunit of this molecule contains the carboxy-terminal peptide of human chorionic gonadotropin, which alters the pharmacokinetic profile of the molecule. It demonstrates a longer circulation half-life and extended time to peak levels when compared with recombinant FSH (rFSH). Like rFSH, it lacks luteinizing hormone activity and binds specifically to the FSH receptor in vitro. Clinical trials show that corifollitropin alfa is able to sustain multiple follicular growth for a week, with a similar ovarian response and safety profile as rFSH. A single injection of corifollitropin alfa can replace 7 daily injections of rFSH during the first week of ovarian stimulation in gonadotropin-releasing hormone antagonist protocols. Therefore, corifollitropin alfa addresses the need for a simplified treatment approach to lessen the burden of multiple daily injections for in vitro fertilization.
注射用重组人促卵泡激素（艾泽®）是首个具有持续促卵泡活性的杂交促卵泡激素（FSH）分子。该分子的β亚基包含人绒毛膜促性腺激素的羧基末端肽，这改变了分子的药代动力学特征。与重组FSH（rFSH）相比，它具有更长的循环半衰期和达到峰值水平的延长时间。与rFSH一样，它缺乏促黄体生成素活性，并且在体外特异性结合FSH受体。临床试验表明，注射用重组人促卵泡激素能够维持多个卵泡生长一周，其卵巢反应和安全性与rFSH相似。在促性腺激素释放激素拮抗剂方案的卵巢刺激的第一周，单次注射注射用重组人促卵泡激素可以替代每日7次注射rFSH。因此，注射用重组人促卵泡激素满足了简化治疗方法的需求，以减轻体外受精每日多次注射的负担。
